Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 1997

View Archived Issues

Pfizer's CP-148623 lowers serum cholesterol in humans

Results from analysis of 10 years of amiodarone therapy presented

Sanofi claims HLE inhibitors

Pharma Mar isolates new cytotoxic agents from marine sponge

Squalene synthase inhibitors reported by Takeda

AMPA/NMDA receptor antagonists from Rhone-Poulenc Rorer

Kaneka discloses anti-H. pylori rifamycins

Prokinetic agents from Kyorin

Cyclic hexapeptide antitumor agents described by Taisho

Daiichi and Fuji prepare new analgesics

Gilead's cidofovir injection approved in the European Union

OraVax: Q1 1997 highlights

Biosource Technologies awarded NIH grant to develop melanin as an antiinflammatory compound

Neurotrophic factor gene therapy shows promise for motor neuron diseases

Chiron and DepoTech complete NDA for DepoCyt

AGM-1470 may have potential for controlling fertility

Progress report on Cypros's adenosine and neuronal calcium channel preclinical programs

ABT-431 evaluated in Parkinson's patients

Hybridon and the Institute of Human Virology enter antisense AIDS therapy collaboration

SIBIA identifies biochemical marker for Alzheimer's disease

Clinical efficacy of Myotrophin in ALS and postpolio syndrome

Salix to commence clinical trials with Normix

Rhone-Poulenc Rorer licenses Granocyte for additional countries

Cytel and Schwarz terminate research collaboration

Neuromyalgic response to rhNGF described

Helix BioPharma enters research and development agreement

FDA grants SciClone orphan drug status for CPX

FDA clears generic version of SKB's Compazine

Transdermal N-0923 effective in Parkinson's disease

COX-2 inhibitor shows potential for preventing neuronal death

Preclinical studies with sodium channel blockers in traumatic brain injury

BioCryst commences phase I trial of HIV compound

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...